Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Moleculin Biotech ( (MBRX) ) has shared an announcement.
On April 23, 2026, Moleculin Biotech reported new preclinical data at the American Association for Cancer Research Annual Meeting 2026 showing strong activity of its lead drug candidate, liposomal Annamycin (L-ANN), in pancreatic ductal adenocarcinoma models. The non-cardiotoxic anthracycline significantly inhibited tumor growth across orthotopic human and syngeneic models and extended median survival by more than 60% in a metastatic model, indicating potential relevance in aggressive pancreatic cancer.
The data also showed substantially higher accumulation of Annamycin in pancreatic tissue and tumors versus doxorubicin, offering a mechanistic explanation for its efficacy where traditional anthracyclines have struggled. L-ANN further induced immune activation, including increased CD8+ and CD4+ T-cell infiltration, suggesting it could turn immunologically “cold” pancreatic tumors into responders and support combination strategies with checkpoint and KRAS inhibitors while maintaining a favorable, non-cardiotoxic safety profile.
These findings align with the activity Moleculin has observed for Annamycin in hematologic and solid tumor settings and support its broader positioning as a platform anthracycline across high-need cancer indications. For stakeholders, the results strengthen the strategic rationale behind Moleculin’s ongoing pivotal MIRACLE trial in relapsed or refractory AML and may enhance the company’s standing in oncology drug development if the preclinical promise translates into clinical benefit.
The most recent analyst rating on (MBRX) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and sustained cash burn) and a technically weak longer-term trend (below key moving averages). Positive clinical/IP-related corporate developments provide some offset, but valuation support is limited due to negative earnings and no dividend.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on developing therapies for hard-to-treat tumors and viral diseases. Its lead program, Annamycin (naxtarubicin), is a next-generation anthracycline designed to avoid multidrug resistance and cardiotoxicity, and is in development for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
The company is running the global pivotal MIRACLE Phase 3 trial of AnnAraC, a combination of Annamycin and cytarabine, in adults with relapsed or refractory acute myeloid leukemia. Moleculin is also advancing WP1066, an immune/transcription modulator targeting oncogenic pathways in brain, pancreatic and other cancers, and WP1122, an antimetabolite candidate for pathogenic viruses and certain cancers.
Average Trading Volume: 153,629
Technical Sentiment Signal: Sell
Current Market Cap: $13.5M
See more data about MBRX stock on TipRanks’ Stock Analysis page.